News
-
2020-11 11MORE
3D Medicines Obtained Exclusive Authorization for the Development and Commercialization in Greater China for AVB-500, a New Anti-cancer Drug from Nasdaq-listed Aravive
Shanghai, November 11, 2020, and Houston, TX, United States, November 10, 2020 – 3D Medicines, Inc., a biopharmaceutical company focusing on the R&D and commercialization of innovative immuno-oncology drugs, and Aravive, Inc. (Nasdaq: ARAV), a new biopharmaceutical company, today announced an exclusive collaboration and license agreement for the development and commercialization of AVB-500 in mainland China, Hong Kong, Macau, and Taiwan (Greater China).
-
2020-10 27MORE
3D Medicines Announced the Collaboration with Haihe Biopharma to Obtain the Exclusive Authorization for Development, Production and Commercialization for Two New Analgesic Drugs in China
Shanghai, October 27, 2020 - 3D Medicines, Inc. (3D Medicines) and Shanghai Haihe Pharmaceutical Co.,Ltd (Haihe Biopharma) today announced a collaboration agreement on Haihe Biopharma‘s innovative analgesics of RMX1001 and RMX1002. 3D Medicines will obtain the exclusive authorization for R&D, production and commercialization of RMX1001 and RMX1002 in China，which was an important move for 3D Medicines to envision a future when cancer is managed as a chronic disease, helping to further form a highly complementary pipeline of 3D Medicines.
-
2020-10 22MORE
3D Medicines Signed Strategic Collaboration with XtalPi, Pushing forward the R&D of Immuno-oncology Drugs Together
October 22, 2020 – 3D Medicines, Inc., a biopharmaceutical company focusing on the R&D and commercialization of immuno-oncology drugs, announced the strategic collaboration agreement on new drug discovery with XtalPi, a leading AI drug development technology company.
-
2020-10 16MORE
3D Medicines' New Laboratory Building for Translational Medicine Center Came into Service and R&D Capabilities Continued to Grow
Shanghai, October 16, 2020 – 3D Medicines announced that a new laboratory building for Translational Medicine Center came into service, and the R&D capabilities continued to grow.
-
2020-10 08MORE
Focusing on the R&D and Commercialization of Immuno-oncology Drugs, 3D Medicines Raised $140 Million in First-round Financing
October 8, 2020，3D Medicines, Inc., a clinical stage biopharmaceutical company focusing on the development and commercialization of differentiated immuno-oncology drugs, announced the completion of the first-round of financing after the spin-off, the total size of the round of financing of 140 million U.S. dollars, or about 970 million yuan.
